8-pivaloyloxygeranyl acetate | 117421-69-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 8-pivaloyloxygeranyl acetate
• 英文别名: [(2E,6E)-8-acetyloxy-2,6-dimethylocta-2,6-dienyl] 2,2-dimethylpropanoate
• CAS: 117421-69-9
• 化学式: C₁₇H₂₈O₄
• 分子量: 296.407
• InChiKey: CRQSSWQXTDCQCB-JUCMHCFKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-pivaloyloxygeranyl acetate 在 甲醇 、 碘 、 potassium carbonate 、 对甲苯磺酸 、 magnesium 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 (11S)-10,11-dihydrogeranylgeraniol
  参考文献：
  名称：

  Synthesis of (1S,2R,12S)-2-hydroxy-11-dihydroneocembrene

  摘要：

  Aiming at the asymmetric total synthesis of trinervitane-type diterpenes, an efficient synthetic route to the title compound was explored starting from the THP ether of pivaloyloxy geraniol 11e. The coupling reaction with Grignard reagent 14 bearing the stereogenic carbon proceeded smoothly to give the THP ether of (11S)-10-dihydrogeranylgeraniol 10. Conversion to the corresponding acid chloride through the intermediate 9, followed by cyclization, afforded the dihydrocembrene derivative 8, from which the title compound 7 was prepared. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(99)00376-6
• 作为产物：
  描述：

  乙酸香叶酯 在 4-二甲氨基吡啶 、 selenium(IV) oxide 、 sodium tetrahydroborate 、 乙醇 、 三乙胺 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 18.0h， 生成 8-pivaloyloxygeranyl acetate
  参考文献：
  名称：

  EP2636663

  摘要：

  公开号：

文献信息

• Macroring contraction methodology
  作者：Takashi Takahashi、Hisao Nemoto、Yutaka Kanda、Jiro Tsuji、Yoshimasa Fukazawa、Toshiya Okajima、Yutaka Fujise

  DOI：10.1016/s0040-4020(01)87733-4

  日期：1987.1

  A new route to construct the carbon skeleton of germacrane sesquiterpenes is described wherein the 13-membered diallylic ethers 12 and 41, prepared by intramolecular O-alkylation of the bromo alcohol and C-alkylation of the cyanohydrin ether respectively, undergo [2,3]-Wittig rearrangement to give the ten-membered carbocycles. Diastereoselectivity in [2,3]-Wittig rearrangement is discussed based on

  描述了一种新的方法来构建胚芽倍半萜的碳骨架，其中分别通过溴醇的分子内O-烷基化和氰醇醚的C-烷基化制备的13元二烯丙基醚12和41经历[2,3]。 -威蒂格重排以产生十元碳环自行车。基于ab-initio计算，基于MM2过渡结构模型，讨论了[2,3] -Wittig重排中的非对映选择性。
• Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient
  申请人：Saimoto Hiroyuki

  公开号：US20130296422A1

  公开（公告）日：2013-11-07

  Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R 1 represents a hydrogen atom; R 2 represents a hydrogen atom or a C 1-7 alkyl group; R 3 represents —CHO, —C(═O)R 5 , —COOR 5 (wherein R 5 represents a C 1-7 alkyl group), —CH 2 OH or —COOH; and R 4 represents a C 1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C 2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C 2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.

  以下新化合物对于预防或治疗由原虫引起的疾病是有用的。其中至少一种由公式（I）表示的化合物（其中，X表示氢原子或卤素原子；R1表示氢原子；R2表示氢原子或C1-7烷基；R3表示—CHO，—C（═O）R5，—COOR5（其中R5表示C1-7烷基），—CH2OH或—COOH；R4表示具有一个或多个取代基的C1-16烷基，在末端碳原子和/或非末端碳原子上，具有一个或多个取代基的C2-16烯基，或者具有一个或多个取代基的C2-16炔基），其光学异构体和药学上可接受的盐被使用。
• DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR
  申请人：NAI INC.

  公开号：US20150166498A1

  公开（公告）日：2015-06-18

  The present invention provides a novel dihydroorotic acid dehydrogenase inhibitor which is applicable to various diseases. When used as an active ingredient, a compound represented by formula (I): (wherein X represents a halogen atom, R 1 represents a hydrogen atom, R 2 represents an alkyl group containing 1 to 7 carbon atoms, R 3 represents —CHO, and R 4 represents —CH 2 —CH═C(CH 3 )—R 0 (wherein R 0 represents an alkyl group containing 1 to 12 carbon atoms which may have a substituent on the terminal carbon and/or on a non-terminal carbon, etc.)), an optical isomer thereof or a pharmaceutically acceptable salt thereof has a high inhibitory effect on dihydroorotic acid dehydrogenase and can be used as an immunosuppressive agent, a therapeutic agent for rheumatism, an anticancer agent, a therapeutic agent for graft rejection, an antiviral agent, an anti- H. pylori agent, a therapeutic agent for diabetes or the like.

  本发明提供了一种新型的二氢乳酸酸脱氢酶抑制剂，可用于多种疾病。当用作活性成分时，式（I）所表示的化合物：（其中X表示卤素原子，R1表示氢原子，R2表示含有1至7个碳原子的烷基，R3表示—CHO，R4表示—CH2—CH═C(CH3)—R0（其中R0表示含有1至12个碳原子的烷基，其末端碳和/或非末端碳上可能有取代基等），其光学异构体或其药学上可接受的盐对二氢乳酸酸脱氢酶具有高抑制作用，可用作免疫抑制剂、治疗风湿病的药物、抗癌药物、移植排斥治疗药物、抗病毒药物、抗H. pylori药物、糖尿病治疗药物或类似药物。
• NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：aRigen Pharmaceuticals, Inc.

  公开号：EP2636663A1

  公开（公告）日：2013-09-11

  Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents -CHO, -C(=O)R5, -COOR5 (wherein R5 represents a C1-7 alkyl group), -CH2OH or -COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.

  以下新型化合物可用于预防或治疗由原生动物引起的疾病。至少一种由式（I）代表的化合物 (其中，X 代表氢原子或卤原子；R1 代表氢原子；R2 代表氢原子或 C1-7 烷基；R3 代表 -CHO、-C(＝O)R5、-COOR5（其中 R5 代表 C1-7 烷基）、-CH2OH 或 -COOH；和 R4 代表在末端碳原子和/或非末端碳原子上具有一个或多个取代基的 C1-16 烷基、在末端碳原子和/或非末端碳原子上具有一个或多个取代基的 C2-16 烯基或在末端碳原子和/或非末端碳原子上具有一个或多个取代基的 C2-16 烷基）、其光学异构体和药学上可接受的盐。
• EP2636663
  申请人：——

  公开号：——

  公开（公告）日：——